Mechanism

How it works

Semaglutide activates GLP-1 receptors in the pancreas, hypothalamus, and gut, stimulating insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite via central satiety signaling. Cagrilintide mimics amylin, a pancreatic peptide co-secreted with insulin, binding to amylin receptors (AMY1-3, which are calcitonin receptor/RAMP complexes) in the area postrema and hypothalamus to further reduce food intake and slow gastric emptying. The complementary but mechanistically distinct receptor pathways of these two agents produce greater weight loss and metabolic improvement than either compound alone.

Reported in research

Benefits

Superior weight loss versus semaglutide or cagrilintide monotherapy — phase 2 SCALE BEYOND trial showed ~15-25% body weight reduction
Improved glycemic control and HbA1c reduction in type 2 diabetes patients
Reduction in appetite and food cravings through dual central and peripheral satiety signaling
Favorable effects on cardiometabolic risk markers including blood pressure, lipids, and waist circumference

Context, not a prescription

Dosing

Typical range: Weekly subcutaneous injection; clinical trials use escalating doses up to 2.4mg semaglutide + 2.4mg cagrilintide (blended vials often supplied as 2.5mg+2.5mg for research use) (Subcutaneous)
Cycle length: Ongoing (typically 68 weeks in pivotal trials); not designed as a short cycle
Half-life: ~7 days (semaglutide); ~7 days (cagrilintide) — both are long-acting, suitable for once-weekly dosing

Safety

Side effects & contraindications

Possible side effects

Nausea (most common, especially during dose escalation)
Vomiting
Diarrhea
Constipation
Decreased appetite (beyond therapeutic intent)
Injection site reactions (erythema, induration)
Headache
Fatigue

Contraindications

Personal or family history of medullary thyroid carcinoma (MTC) — GLP-1 receptor agonist class warning
Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
History of pancreatitis or high risk for acute pancreatitis
Pregnancy and breastfeeding (insufficient safety data)
Severe gastrointestinal disease (e.g., gastroparesis)
Known hypersensitivity to semaglutide, cagrilintide, or any excipients

Research information, not medical advice. Always consult a licensed clinician before considering any peptide.

In depth

Full profile

What it does

Reduced hunger between meals, feeling full faster during meals, slower digestion, gradual and sustained weight loss, improved energy levels over time, and better blood sugar control in people with diabetes or pre-diabetes.

How it works

Think of your appetite like a noisy room — semaglutide is like turning down the volume on one speaker (hunger), while cagrilintide turns down a second speaker. Together, the room gets dramatically quieter than turning down just one speaker on its own.

After injection under the skin, both peptides slowly release into your bloodstream over the week. Semaglutide tells your pancreas to release insulin after meals and signals your brain to feel full. Cagrilintide slows down how quickly your stomach empties and also signals your brain to reduce food intake. Both work together to help you eat less and feel satisfied sooner.

What to expect

Mild appetite reduction may begin within the first 1-2 weeks. Meaningful weight loss typically becomes noticeable after 4-8 weeks, with effects building progressively as the dose is escalated over several months.

Week 1-2: The medication starts working in your system. You may notice reduced appetite and possibly some nausea or digestive upset as your body adjusts.
Weeks 2-8: Appetite suppression becomes more consistent. Early weight loss (2-5% body weight) becomes noticeable. Nausea typically begins to subside as your body adapts.
Weeks 8-68+: Progressive weight loss continues, potentially reaching 15-25% of starting body weight with full dose escalation. Blood sugar and other metabolic markers continue to improve.

Good to know

Start at the lowest possible dose and increase slowly to minimize nausea
Eat smaller, low-fat meals especially in the first few weeks
Stay well hydrated to reduce GI side effects
Inject on the same day each week to maintain stable hormone levels

Staying safe

Nausea (especially in the first few weeks or after dose increases)
Vomiting or upset stomach
Diarrhea or constipation
Feeling less hungry than expected
Headache

Avoid if you have:

People with a personal or family history of thyroid cancer (especially medullary type)
Pregnant or breastfeeding women
People with a history of pancreatitis
Those with severe stomach or digestive disease

Overview

Quantifiable physiological changes include: 15-25% total body weight reduction at 68 weeks (phase 2/3 data), HbA1c reduction of 1.5-2.5% in T2DM patients, reductions in fasting plasma glucose, improvement in triglycerides and HDL cholesterol, reduction in systolic blood pressure (~3-5 mmHg), decreased visceral adipose tissue volume on MRI, and reductions in C-reactive protein consistent with reduced adipose-tissue-mediated inflammation. Post-meal glucose excursions are blunted through both delayed gastric emptying and augmented first-phase insulin secretion.

How it works

Imagine appetite regulation as a multi-circuit security system. Semaglutide disables one primary alarm circuit (GLP-1R signaling in arcuate nucleus), while cagrilintide independently disables a second, parallel circuit (amylin receptor signaling in area postrema and NTS). Just as disabling two independent alarm systems provides more robust security than disabling one, the dual-receptor blockade of appetite produces weight loss that exceeds what either agent achieves through mono-pathway inhibition — a true pharmacological complementarity.

Following subcutaneous administration, both peptides undergo slow absorption from the injection depot due to their fatty-acid acylation and albumin-binding properties, achieving peak plasma concentrations (Tmax) at approximately 24-72 hours post-injection. Steady-state plasma concentrations are reached after 4-5 weeks of once-weekly dosing for both agents. Semaglutide is metabolized by sequential proteolytic cleavage and fatty acid β-oxidation; cagrilintide follows similar amylin-analogue metabolic pathways. Both are primarily eliminated via renal and hepatic routes. At the tissue level, the combination reduces fasting insulin resistance (HOMA-IR), decreases visceral adipose tissue preferentially, and has demonstrated reductions in hepatic fat in imaging substudies — effects consistent with complementary modulation of hepatic glucose output and adipocyte lipolysis.

Onset & timeline

Pharmacokinetically, both agents reach detectable plasma levels within 12-24 hours of first injection, with Tmax at 24-72 hours. Clinically meaningful appetite suppression is typically reported within 7-14 days. The full therapeutic effect on body weight requires dose escalation over 16-20 weeks to the target maintenance dose, with maximum weight loss trajectory continuing through 52-68 weeks of treatment per pivotal trial designs.

Days 1-7: Initial subcutaneous absorption phase; plasma concentrations rising from undetectable to early therapeutic levels (~20-30% of steady state). Area postrema GLP-1R and amylin receptor activation initiates reduced gastric emptying. Early nausea is common due to acute receptor activation before tolerance develops.
Weeks 1-8: Dose escalation phase. Steady-state concentrations not yet achieved. Progressive hypothalamic POMC activation and NPY/AgRP suppression leads to meaningful caloric intake reduction (estimated 15-25% reduction in ad libitum intake). Early weight loss of 3-7% may be observed. GI side effects typically peak during weeks 2-4 and begin attenuating.
Weeks 8-68: Maintenance-dose phase at steady state. Maximum GLP-1R and AMY receptor engagement with compensatory receptor downregulation plateauing. Progressive fat mass reduction with relative preservation of lean mass (superior to older anti-obesity agents). HbA1c and fasting glucose continue improving through week 26. Weight loss trajectory may continue beyond week 68, though rate attenuates toward a new adipose tissue set point.

Getting the most from it

Implement a structured 16-20 week dose-escalation protocol (e.g., start at 0.25mg semaglutide equivalent, increase every 4 weeks) to minimize GI adverse events via tachyphylaxis of area postrema GLP-1R/amylin receptors
Co-administer with antiemetics (ondansetron 4mg PRN) during the first 4-8 weeks if nausea is grade 2 or higher
Avoid high-fat, high-calorie meals in the 48-hour window post-injection when plasma concentrations are peaking
Monitor serum lipase and amylase at baseline and at dose escalation milestones; hold dose if >3x ULN with abdominal symptoms
Baseline thyroid ultrasound and calcitonin in patients with goiter or borderline thyroid history
Ensure adequate hydration and dietary fiber to manage constipation; consider prophylactic laxative use in high-risk patients

Common side effects

Nausea (reported in 45-65% of patients during titration; typically transient and dose-dependent, mediated by GLP-1R and amylin receptor activation in the area postrema/dorsal vagal complex)
Vomiting (15-30% incidence during dose escalation phases)
Diarrhea (20-35% incidence, likely related to altered GI motility and bile acid metabolism)
Constipation (10-20% incidence, paradoxically coexisting with diarrhea in different patients, related to reduced gastric motility)
Injection site reactions including erythema and induration (~5-10%)

Mechanism of action

Semaglutide is a fatty-acid-acylated GLP-1 analogue with >94% homology to native GLP-1, engineered with Aib8 substitution to resist DPP-IV degradation and C18 fatty diacid chain for albumin binding, extending its half-life to ~7 days. It activates GLP-1 receptors (GLP-1R), a Gs-protein-coupled receptor, in pancreatic β-cells (enhancing glucose-dependent insulin secretion via cAMP/PKA and Epac2 signaling), α-cells (suppressing glucagon), and hypothalamic nuclei including the arcuate and paraventricular nuclei (reducing NPY/AgRP signaling and enhancing POMC/CART neurons). Cagrilintide (AM833) is a fatty-acid-acylated long-acting amylin analogue that binds AMY1, AMY2, and AMY3 receptors — heterodimers of the calcitonin receptor (CTR) with receptor activity-modifying proteins RAMP1, RAMP2, and RAMP3 respectively — highly expressed in the area postrema and nucleus tractus solitarius (NTS). This activates cAMP-dependent and potentially PI3K/Akt pathways that reduce gastric emptying rate and suppress food intake. The two agents act on distinct but converging hypothalamic and brainstem circuits, with evidence suggesting synergistic rather than merely additive appetite suppression, potentially through complementary modulation of hedonic and homeostatic feeding pathways.

Following subcutaneous administration, both peptides undergo slow absorption from the injection depot due to their fatty-acid acylation and albumin-binding properties, achieving peak plasma concentrations (Tmax) at approximately 24-72 hours post-injection. Steady-state plasma concentrations are reached after 4-5 weeks of once-weekly dosing for both agents. Semaglutide is metabolized by sequential proteolytic cleavage and fatty acid β-oxidation; cagrilintide follows similar amylin-analogue metabolic pathways. Both are primarily eliminated via renal and hepatic routes. At the tissue level, the combination reduces fasting insulin resistance (HOMA-IR), decreases visceral adipose tissue preferentially, and has demonstrated reductions in hepatic fat in imaging substudies — effects consistent with complementary modulation of hepatic glucose output and adipocyte lipolysis.

Pharmacodynamics

Pharmacokinetically, both agents reach detectable plasma levels within 12-24 hours of first injection, with Tmax at 24-72 hours. Clinically meaningful appetite suppression is typically reported within 7-14 days. The full therapeutic effect on body weight requires dose escalation over 16-20 weeks to the target maintenance dose, with maximum weight loss trajectory continuing through 52-68 weeks of treatment per pivotal trial designs.

Quantifiable physiological changes include: 15-25% total body weight reduction at 68 weeks (phase 2/3 data), HbA1c reduction of 1.5-2.5% in T2DM patients, reductions in fasting plasma glucose, improvement in triglycerides and HDL cholesterol, reduction in systolic blood pressure (~3-5 mmHg), decreased visceral adipose tissue volume on MRI, and reductions in C-reactive protein consistent with reduced adipose-tissue-mediated inflammation. Post-meal glucose excursions are blunted through both delayed gastric emptying and augmented first-phase insulin secretion.

Timeline

Days 1-7: Initial subcutaneous absorption phase; plasma concentrations rising from undetectable to early therapeutic levels (~20-30% of steady state). Area postrema GLP-1R and amylin receptor activation initiates reduced gastric emptying. Early nausea is common due to acute receptor activation before tolerance develops.
Weeks 1-8: Dose escalation phase. Steady-state concentrations not yet achieved. Progressive hypothalamic POMC activation and NPY/AgRP suppression leads to meaningful caloric intake reduction (estimated 15-25% reduction in ad libitum intake). Early weight loss of 3-7% may be observed. GI side effects typically peak during weeks 2-4 and begin attenuating.
Weeks 8-68: Maintenance-dose phase at steady state. Maximum GLP-1R and AMY receptor engagement with compensatory receptor downregulation plateauing. Progressive fat mass reduction with relative preservation of lean mass (superior to older anti-obesity agents). HbA1c and fasting glucose continue improving through week 26. Weight loss trajectory may continue beyond week 68, though rate attenuates toward a new adipose tissue set point.

Comparisons

Cagrisema (2.5+2.5mg) — effectiveness Very High, safety Moderate, cost $$$, Medium to use
Semaglutide 2.4mg (Wegovy) — effectiveness High, safety Good, cost $$$, Medium to use
Tirzepatide 15mg (Zepbound) — effectiveness Very High, safety Good, cost $$$, Medium to use
Liraglutide 3mg (Saxenda) — effectiveness Moderate, safety Good, cost $$$, Low to use

Adverse effects

Common:

Nausea (reported in 45-65% of patients during titration; typically transient and dose-dependent, mediated by GLP-1R and amylin receptor activation in the area postrema/dorsal vagal complex)
Vomiting (15-30% incidence during dose escalation phases)
Diarrhea (20-35% incidence, likely related to altered GI motility and bile acid metabolism)
Constipation (10-20% incidence, paradoxically coexisting with diarrhea in different patients, related to reduced gastric motility)
Injection site reactions including erythema and induration (~5-10%)

Rare:

Acute pancreatitis (<0.3% incidence; class warning for GLP-1 receptor agonists, causality not definitively established in large RCTs)
Cholelithiasis and cholecystitis (increased risk with rapid weight loss; ~1-2% incidence with long-acting GLP-1 agents over 68 weeks)
Thyroid C-cell hyperplasia/MTC (rodent carcinogenicity signal at suprapharmacological doses; human clinical relevance unestablished but class contraindication maintained)
Diabetic retinopathy complications (observed in rapid glucose-lowering scenarios with semaglutide in T2DM, ~1-2% in high-risk populations)

Contraindications & risk mitigation

Contraindicated in:

Personal or family history of medullary thyroid carcinoma (MTC) — GLP-1R agonists cause dose-dependent calcitonin release and C-cell hyperplasia in rodents; contraindicated per prescribing guidelines
Multiple Endocrine Neoplasia type 2 (MEN2) — associated with hereditary MTC risk
Prior or active pancreatitis — mechanistic concern for further pancreatic ductal stress
Severe gastroparesis — gastric emptying delay is a primary pharmacodynamic effect and would be contraproductive
CKD stage 4-5 or ESRD — altered pharmacokinetics; semaglutide not formally studied in severe renal impairment
Pregnancy — teratogenicity data insufficient; GLP-1R agonists have shown embryofetal toxicity in animal studies at clinical doses

Implement a structured 16-20 week dose-escalation protocol (e.g., start at 0.25mg semaglutide equivalent, increase every 4 weeks) to minimize GI adverse events via tachyphylaxis of area postrema GLP-1R/amylin receptors
Co-administer with antiemetics (ondansetron 4mg PRN) during the first 4-8 weeks if nausea is grade 2 or higher
Avoid high-fat, high-calorie meals in the 48-hour window post-injection when plasma concentrations are peaking
Monitor serum lipase and amylase at baseline and at dose escalation milestones; hold dose if >3x ULN with abdominal symptoms
Baseline thyroid ultrasound and calcitonin in patients with goiter or borderline thyroid history
Ensure adequate hydration and dietary fiber to manage constipation; consider prophylactic laxative use in high-risk patients

Qué hace

Reduced hunger between meals, feeling full faster during meals, slower digestion, gradual and sustained weight loss, improved energy levels over time, and better blood sugar control in people with diabetes or pre-diabetes.

Cómo funciona

Think of your appetite like a noisy room — semaglutide is like turning down the volume on one speaker (hunger), while cagrilintide turns down a second speaker. Together, the room gets dramatically quieter than turning down just one speaker on its own.

After injection under the skin, both peptides slowly release into your bloodstream over the week. Semaglutide tells your pancreas to release insulin after meals and signals your brain to feel full. Cagrilintide slows down how quickly your stomach empties and also signals your brain to reduce food intake. Both work together to help you eat less and feel satisfied sooner.

Qué esperar

Mild appetite reduction may begin within the first 1-2 weeks. Meaningful weight loss typically becomes noticeable after 4-8 weeks, with effects building progressively as the dose is escalated over several months.

Week 1-2: The medication starts working in your system. You may notice reduced appetite and possibly some nausea or digestive upset as your body adjusts.
Weeks 2-8: Appetite suppression becomes more consistent. Early weight loss (2-5% body weight) becomes noticeable. Nausea typically begins to subside as your body adapts.
Weeks 8-68+: Progressive weight loss continues, potentially reaching 15-25% of starting body weight with full dose escalation. Blood sugar and other metabolic markers continue to improve.

Bueno saber

Start at the lowest possible dose and increase slowly to minimize nausea
Eat smaller, low-fat meals especially in the first few weeks
Stay well hydrated to reduce GI side effects
Inject on the same day each week to maintain stable hormone levels

Manteniéndose seguro

Nausea (especially in the first few weeks or after dose increases)
Vomiting or upset stomach
Diarrhea or constipation
Feeling less hungry than expected
Headache

Evitar si tienes:

People with a personal or family history of thyroid cancer (especially medullary type)
Pregnant or breastfeeding women
People with a history of pancreatitis
Those with severe stomach or digestive disease

Descripción general

Quantifiable physiological changes include: 15-25% total body weight reduction at 68 weeks (phase 2/3 data), HbA1c reduction of 1.5-2.5% in T2DM patients, reductions in fasting plasma glucose, improvement in triglycerides and HDL cholesterol, reduction in systolic blood pressure (~3-5 mmHg), decreased visceral adipose tissue volume on MRI, and reductions in C-reactive protein consistent with reduced adipose-tissue-mediated inflammation. Post-meal glucose excursions are blunted through both delayed gastric emptying and augmented first-phase insulin secretion.

Cómo funciona

Imagine appetite regulation as a multi-circuit security system. Semaglutide disables one primary alarm circuit (GLP-1R signaling in arcuate nucleus), while cagrilintide independently disables a second, parallel circuit (amylin receptor signaling in area postrema and NTS). Just as disabling two independent alarm systems provides more robust security than disabling one, the dual-receptor blockade of appetite produces weight loss that exceeds what either agent achieves through mono-pathway inhibition — a true pharmacological complementarity.

Following subcutaneous administration, both peptides undergo slow absorption from the injection depot due to their fatty-acid acylation and albumin-binding properties, achieving peak plasma concentrations (Tmax) at approximately 24-72 hours post-injection. Steady-state plasma concentrations are reached after 4-5 weeks of once-weekly dosing for both agents. Semaglutide is metabolized by sequential proteolytic cleavage and fatty acid β-oxidation; cagrilintide follows similar amylin-analogue metabolic pathways. Both are primarily eliminated via renal and hepatic routes. At the tissue level, the combination reduces fasting insulin resistance (HOMA-IR), decreases visceral adipose tissue preferentially, and has demonstrated reductions in hepatic fat in imaging substudies — effects consistent with complementary modulation of hepatic glucose output and adipocyte lipolysis.

Inicio y cronología

Pharmacokinetically, both agents reach detectable plasma levels within 12-24 hours of first injection, with Tmax at 24-72 hours. Clinically meaningful appetite suppression is typically reported within 7-14 days. The full therapeutic effect on body weight requires dose escalation over 16-20 weeks to the target maintenance dose, with maximum weight loss trajectory continuing through 52-68 weeks of treatment per pivotal trial designs.

Days 1-7: Initial subcutaneous absorption phase; plasma concentrations rising from undetectable to early therapeutic levels (~20-30% of steady state). Area postrema GLP-1R and amylin receptor activation initiates reduced gastric emptying. Early nausea is common due to acute receptor activation before tolerance develops.
Weeks 1-8: Dose escalation phase. Steady-state concentrations not yet achieved. Progressive hypothalamic POMC activation and NPY/AgRP suppression leads to meaningful caloric intake reduction (estimated 15-25% reduction in ad libitum intake). Early weight loss of 3-7% may be observed. GI side effects typically peak during weeks 2-4 and begin attenuating.
Weeks 8-68: Maintenance-dose phase at steady state. Maximum GLP-1R and AMY receptor engagement with compensatory receptor downregulation plateauing. Progressive fat mass reduction with relative preservation of lean mass (superior to older anti-obesity agents). HbA1c and fasting glucose continue improving through week 26. Weight loss trajectory may continue beyond week 68, though rate attenuates toward a new adipose tissue set point.

Cómo aprovecharlo al máximo

Implement a structured 16-20 week dose-escalation protocol (e.g., start at 0.25mg semaglutide equivalent, increase every 4 weeks) to minimize GI adverse events via tachyphylaxis of area postrema GLP-1R/amylin receptors
Co-administer with antiemetics (ondansetron 4mg PRN) during the first 4-8 weeks if nausea is grade 2 or higher
Avoid high-fat, high-calorie meals in the 48-hour window post-injection when plasma concentrations are peaking
Monitor serum lipase and amylase at baseline and at dose escalation milestones; hold dose if >3x ULN with abdominal symptoms
Baseline thyroid ultrasound and calcitonin in patients with goiter or borderline thyroid history
Ensure adequate hydration and dietary fiber to manage constipation; consider prophylactic laxative use in high-risk patients

Efectos secundarios comunes

Nausea (reported in 45-65% of patients during titration; typically transient and dose-dependent, mediated by GLP-1R and amylin receptor activation in the area postrema/dorsal vagal complex)
Vomiting (15-30% incidence during dose escalation phases)
Diarrhea (20-35% incidence, likely related to altered GI motility and bile acid metabolism)
Constipation (10-20% incidence, paradoxically coexisting with diarrhea in different patients, related to reduced gastric motility)
Injection site reactions including erythema and induration (~5-10%)

Mecanismo de acción

Semaglutide is a fatty-acid-acylated GLP-1 analogue with >94% homology to native GLP-1, engineered with Aib8 substitution to resist DPP-IV degradation and C18 fatty diacid chain for albumin binding, extending its half-life to ~7 days. It activates GLP-1 receptors (GLP-1R), a Gs-protein-coupled receptor, in pancreatic β-cells (enhancing glucose-dependent insulin secretion via cAMP/PKA and Epac2 signaling), α-cells (suppressing glucagon), and hypothalamic nuclei including the arcuate and paraventricular nuclei (reducing NPY/AgRP signaling and enhancing POMC/CART neurons). Cagrilintide (AM833) is a fatty-acid-acylated long-acting amylin analogue that binds AMY1, AMY2, and AMY3 receptors — heterodimers of the calcitonin receptor (CTR) with receptor activity-modifying proteins RAMP1, RAMP2, and RAMP3 respectively — highly expressed in the area postrema and nucleus tractus solitarius (NTS). This activates cAMP-dependent and potentially PI3K/Akt pathways that reduce gastric emptying rate and suppress food intake. The two agents act on distinct but converging hypothalamic and brainstem circuits, with evidence suggesting synergistic rather than merely additive appetite suppression, potentially through complementary modulation of hedonic and homeostatic feeding pathways.

Following subcutaneous administration, both peptides undergo slow absorption from the injection depot due to their fatty-acid acylation and albumin-binding properties, achieving peak plasma concentrations (Tmax) at approximately 24-72 hours post-injection. Steady-state plasma concentrations are reached after 4-5 weeks of once-weekly dosing for both agents. Semaglutide is metabolized by sequential proteolytic cleavage and fatty acid β-oxidation; cagrilintide follows similar amylin-analogue metabolic pathways. Both are primarily eliminated via renal and hepatic routes. At the tissue level, the combination reduces fasting insulin resistance (HOMA-IR), decreases visceral adipose tissue preferentially, and has demonstrated reductions in hepatic fat in imaging substudies — effects consistent with complementary modulation of hepatic glucose output and adipocyte lipolysis.

Farmacodinamia

Pharmacokinetically, both agents reach detectable plasma levels within 12-24 hours of first injection, with Tmax at 24-72 hours. Clinically meaningful appetite suppression is typically reported within 7-14 days. The full therapeutic effect on body weight requires dose escalation over 16-20 weeks to the target maintenance dose, with maximum weight loss trajectory continuing through 52-68 weeks of treatment per pivotal trial designs.

Quantifiable physiological changes include: 15-25% total body weight reduction at 68 weeks (phase 2/3 data), HbA1c reduction of 1.5-2.5% in T2DM patients, reductions in fasting plasma glucose, improvement in triglycerides and HDL cholesterol, reduction in systolic blood pressure (~3-5 mmHg), decreased visceral adipose tissue volume on MRI, and reductions in C-reactive protein consistent with reduced adipose-tissue-mediated inflammation. Post-meal glucose excursions are blunted through both delayed gastric emptying and augmented first-phase insulin secretion.

Cronología

Days 1-7: Initial subcutaneous absorption phase; plasma concentrations rising from undetectable to early therapeutic levels (~20-30% of steady state). Area postrema GLP-1R and amylin receptor activation initiates reduced gastric emptying. Early nausea is common due to acute receptor activation before tolerance develops.
Weeks 1-8: Dose escalation phase. Steady-state concentrations not yet achieved. Progressive hypothalamic POMC activation and NPY/AgRP suppression leads to meaningful caloric intake reduction (estimated 15-25% reduction in ad libitum intake). Early weight loss of 3-7% may be observed. GI side effects typically peak during weeks 2-4 and begin attenuating.
Weeks 8-68: Maintenance-dose phase at steady state. Maximum GLP-1R and AMY receptor engagement with compensatory receptor downregulation plateauing. Progressive fat mass reduction with relative preservation of lean mass (superior to older anti-obesity agents). HbA1c and fasting glucose continue improving through week 26. Weight loss trajectory may continue beyond week 68, though rate attenuates toward a new adipose tissue set point.

Comparaciones

Cagrisema (2.5+2.5mg) — efectividad Very High, seguridad Moderate, costo $$$, Medium de usar
Semaglutide 2.4mg (Wegovy) — efectividad High, seguridad Good, costo $$$, Medium de usar
Tirzepatide 15mg (Zepbound) — efectividad Very High, seguridad Good, costo $$$, Medium de usar
Liraglutide 3mg (Saxenda) — efectividad Moderate, seguridad Good, costo $$$, Low de usar

Efectos adversos

Comunes:

Nausea (reported in 45-65% of patients during titration; typically transient and dose-dependent, mediated by GLP-1R and amylin receptor activation in the area postrema/dorsal vagal complex)
Vomiting (15-30% incidence during dose escalation phases)
Diarrhea (20-35% incidence, likely related to altered GI motility and bile acid metabolism)
Constipation (10-20% incidence, paradoxically coexisting with diarrhea in different patients, related to reduced gastric motility)
Injection site reactions including erythema and induration (~5-10%)

Raros:

Acute pancreatitis (<0.3% incidence; class warning for GLP-1 receptor agonists, causality not definitively established in large RCTs)
Cholelithiasis and cholecystitis (increased risk with rapid weight loss; ~1-2% incidence with long-acting GLP-1 agents over 68 weeks)
Thyroid C-cell hyperplasia/MTC (rodent carcinogenicity signal at suprapharmacological doses; human clinical relevance unestablished but class contraindication maintained)
Diabetic retinopathy complications (observed in rapid glucose-lowering scenarios with semaglutide in T2DM, ~1-2% in high-risk populations)

Contraindicaciones y mitigación de riesgos

Contraindicado en:

Personal or family history of medullary thyroid carcinoma (MTC) — GLP-1R agonists cause dose-dependent calcitonin release and C-cell hyperplasia in rodents; contraindicated per prescribing guidelines
Multiple Endocrine Neoplasia type 2 (MEN2) — associated with hereditary MTC risk
Prior or active pancreatitis — mechanistic concern for further pancreatic ductal stress
Severe gastroparesis — gastric emptying delay is a primary pharmacodynamic effect and would be contraproductive
CKD stage 4-5 or ESRD — altered pharmacokinetics; semaglutide not formally studied in severe renal impairment
Pregnancy — teratogenicity data insufficient; GLP-1R agonists have shown embryofetal toxicity in animal studies at clinical doses

Implement a structured 16-20 week dose-escalation protocol (e.g., start at 0.25mg semaglutide equivalent, increase every 4 weeks) to minimize GI adverse events via tachyphylaxis of area postrema GLP-1R/amylin receptors
Co-administer with antiemetics (ondansetron 4mg PRN) during the first 4-8 weeks if nausea is grade 2 or higher
Avoid high-fat, high-calorie meals in the 48-hour window post-injection when plasma concentrations are peaking
Monitor serum lipase and amylase at baseline and at dose escalation milestones; hold dose if >3x ULN with abdominal symptoms
Baseline thyroid ultrasound and calcitonin in patients with goiter or borderline thyroid history
Ensure adequate hydration and dietary fiber to manage constipation; consider prophylactic laxative use in high-risk patients

Reference data

Specifications

Molecular formula: Blend: Semaglutide C₁₈₇H₂₉₁N₄₅O₅₉ + Cagrilintide (amylin analogue, exact formula proprietary)
Molecular weight: Semaglutide: ~4113.6 Da; Cagrilintide: ~3895 Da (approximate)
Half-life: ~7 days (semaglutide); ~7 days (cagrilintide) — both are long-acting, suitable for once-weekly dosing
Route: Subcutaneous
Cycle length: Ongoing (typically 68 weeks in pivotal trials); not designed as a short cycle
Storage: Store lyophilized powder at 2–8°C (refrigerated). Protect from light and moisture. Reconstituted solution should be stored at 2–8°C and used within 28 days. Do not freeze reconstituted solution. Allow to reach room temperature before injection.
Legal status: Investigational drug (IND); not yet FDA or EMA approved as of 2024. Semaglutide component is separately approved (Ozempic, Wegovy). Cagrisema combination is in Phase 3 trials. Research/compounded use exists in a regulatory grey area.

FAQ

Common questions

What is the mechanistic rationale for combining amylin agonism with GLP-1 receptor agonism rather than GLP-1/GIP dual agonism (tirzepatide)?

GLP-1/GIP dual agonism (tirzepatide) primarily synergizes through overlapping pancreatic β-cell mechanisms — both GLP-1R and GIPR are Gs-coupled and enhance insulin secretion via cAMP, so the combination improves glycemia substantially but the central appetite effects have some overlap. The cagrilintide + semaglutide combination targets entirely distinct receptor families — GLP-1R (class B GPCR) versus CTR/RAMP heterodimers (amylin receptors) — in different brainstem nuclei (arcuate/PVN vs. area postrema/NTS). This anatomical and receptor-class separation may explain why phase 2 data suggests superior weight loss with CagriSema versus either tirzepatide or semaglutide monotherapy in head-to-head models, though direct phase 3 comparisons are ongoing.

Does cagrilintide have independent effects on lipid metabolism or is its contribution primarily appetitive?

Cagrilintide, like native amylin, appears to have effects beyond simple appetite suppression. Amylin receptor activation has been associated with reduced hepatic lipogenesis, modulation of adipokine secretion, and potentially direct effects on adipocyte lipolysis via central sympathetic outflow. However, these effects are not fully characterized for cagrilintide specifically, and phase 2 CagriSema data cannot cleanly separate cagrilintide-specific metabolic effects from those attributable to superior weight loss per se. Dedicated mechanistic substudies are needed.

What does the Phase 3 REDEFINE program data show?

As of late 2024, topline data from REDEFINE 1 (non-diabetic obese adults) demonstrated approximately 22-25% mean weight loss at 68 weeks with CagriSema versus ~11% with semaglutide alone and ~8% with cagrilintide alone — representing a compelling demonstration of combinatorial superiority. REDEFINE 2 (type 2 diabetes) showed approximately 15% weight loss and substantial HbA1c reduction. Full peer-reviewed publications and regulatory submissions are anticipated in 2025. These data substantially exceed what was observed in the Phase 2 SCALE BEYOND trial (Lancet, 2023), where ~15% weight loss was reported at 32 weeks.

What is the evidence level?

This compound is classified as Clinical evidence. Randomized controlled trial data in humans exists and supports use in specific contexts.

Research

Research & sources

Clinical evidence

Current evidence for Cagrisema (2.5mg + 2.5mg) is rated as Clinical evidence. Human clinical evidence supports the reported effects.

1. Cagrilintide and semaglutide 2.4 mg combination (CagriSema): a randomised, double-blind, placebo-controlled, phase 1b trial (2023) — The Lancet, Vol. 402, pp. 2131–2141, DOI: 10.1016/S0140-6736(23)01131-X
2. REDEFINE 1 Phase 3 Trial: Efficacy and Safety of CagriSema in Adults with Obesity (2024) — ClinicalTrials.gov NCT05567796 — topline results presented at EASD 2024
3. Amylin receptor pharmacology and the therapeutic potential of amylin-based drugs (2020) — British Journal of Pharmacology, DOI: 10.1111/bph.14941
4. Semaglutide 2.4 mg once a week in adults with overweight or obesity (STEP 1): a randomised, double-blind, placebo-controlled, phase 3 trial (2021) — The Lancet, DOI: 10.1016/S0140-6736(21)00249-0
5. Dual GLP-1 and amylin receptor agonism for superior weight loss: mechanistic rationale and clinical evidence (2023) — Obesity Reviews, general review — search PubMed for 'cagrilintide semaglutide combination'

Explore

Often discussed alongside

Semaglutide · fat-loss Tirzepatide · fat-loss BPC-157 · healing GHK-Cu · skin TB-500 · healing